Physician profile
Alice Sui
NPI 1801458849
$2,485.58
in general payments reported to CMS, 2019-2025
22 companies · $692 in 2025
The $692 reported for 2025 was more than what 85% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $309 · 2022: $384 · 2023: $470 · 2024: $632 · 2025: $692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,793.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,793.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $292.41 | 2021-2025 | Cequa |
| Alcon Vision LLC | $260.77 | 2022-2025 | Clareon, Simbrinza, Tryptyr |
| Harrow Eye, LLC | $250.86 | 2024-2025 | Vevye |
| Abbvie INC. | $223.90 | 2022-2024 | Vuity, Lumigan, Alphagan P |
| Tarsus Pharmaceuticals, INC. | $170.36 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $158.95 | 2021-2023 | |
| Bausch & Lomb Americas INC. | $158.65 | 2023-2025 | Infuse, Vyzulta, Biotrue |
| Kala Pharmaceuticals, INC. | $138.32 | 2021-2022 | |
| Thea Pharma INC. | $133.97 | 2022-2025 | Iyuzeh |
| Genentech USA, INC. | $116.63 | 2023-2025 | Vabysmo |
| Allergan, INC. | $113.27 | 2021 | |
| Oyster Point Pharma, INC. | $100.00 | 2023-2025 | Tyrvaya |
| Astellas Pharma US INC | $85.92 | 2025 | Izervay |
| Amgen INC. | $53.74 | 2024 | Tepezza |
| Johnson & Johnson Vision Care, INC. | $49.40 | 2023-2025 | Acuvue |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $47.70 | 2023-2025 | Syfovre |
| Dompe US, INC. | $34.50 | 2025 | Oxervate |
| Horizon Therapeutics Plc | $33.67 | 2023 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $17.95 | 2025 | Tecnis Iol |
| Glaukos Corporation | $17.70 | 2024 | Idose |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.24 | 2021 | |
| Eyevance Pharmaceuticals LLC | $12.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alice Sui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.